Who are Elunate®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): C1 inhibitor (human) [C1 INH], Nafamostat Mesilate, C1 Esterase Inhibitor (Human), Camostat mesylate, C1 esterase inhibitor [human] liquid, Aprotinin (inhaled).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/elunate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Elunate® — Competitive Intelligence Brief

Elunate® (Elunate®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: serine protease inhibitor. Area: Oncology.

phase 2 serine protease inhibitor SERPINFB Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Elunate® (Elunate®) — Hutchmed. Elunate is a small molecule inhibitor of the serine protease inhibitor, serpin family F member 5 (SERPINFB).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Elunate® TARGET	Elunate®	Hutchmed	phase 2	serine protease inhibitor	SERPINFB
C1 inhibitor (human) [C1 INH]	C1 inhibitor (human) [C1 INH]	Shire	marketed	Complement inhibitor / Serine protease inhibitor	C1s protease / Classical complement pathway
Nafamostat Mesilate	Nafamostat Mesilate	Chong Kun Dang Pharmaceutical	marketed	Serine protease inhibitor	Serine proteases (thrombin, factor Xa, kallikrein, trypsin)
C1 Esterase Inhibitor (Human)	C1 Esterase Inhibitor (Human)	Shire	marketed	Serine protease inhibitor; complement regulator	C1 esterase inhibitor (C1-INH); Factor XIIa; plasma kallikrein
Camostat mesylate	Camostat mesylate	Seoul National University Hospital	phase 3	Serine protease inhibitor	TMPRSS2 (Transmembrane Protease Serine 2)
C1 esterase inhibitor [human] liquid	C1 esterase inhibitor [human] liquid	Shire	phase 3	Serine protease inhibitor; plasma-derived protein replacement	C1 esterase inhibitor (C1-INH); Factor XIIa, Factor XIa, Kallikrein
Aprotinin (inhaled)	Aprotinin (inhaled)	Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion	phase 3	Serine protease inhibitor	Kallikrein, plasmin, trypsin, and other serine proteases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (serine protease inhibitor class)

Hutchmed · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elunate® — Competitive Intelligence Brief. https://druglandscape.com/ci/elunate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab